Table 2.

Overall Response, as Assessed at an Independent Review Facility.^*

Response	Placebo plus Trastuzumab plus Docetaxel (N = 336)	Pertuzumab plus Trastuzumab plus Docetaxel (N = 343)
	number (percent)
Objective response	233 (69.3)	275 (80.2)
Complete response	14 (4.2)	19 (5.5)
Partial response	219 (65.2)	256 (74.6)
Stable disease	70 (20.8)	50 (14.6)
Progressive disease	28 (8.3)	13 (3.8)
Not assessable	2 (0.6)	2 (0.6)
No assessment performed	3 (0.9)	3 (0.9)

^*Total numbers in the two groups represent the number of patients with measurable disease at baseline, as assessed at an independent review facility.